key: cord-0996115-613s5ya5
authors: Potere, Nicola; Di Nisio, Marcello; Rizzo, Giulia; La Vella, Matteo; Polilli, Ennio; Agostinone, Adriana; Spacone, Antonella; Di Carlo, Silvio; Costantini, Alberto; Abbate, Antonio; Porreca, Ettore; Parruti, Giustino
title: Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation
date: 2020-08-06
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.07.078
sha: 0fef31327679a434620a4bd182764591a31ac502
doc_id: 996115
cord_uid: 613s5ya5

AIM: The aim of the study was to evaluate the safety and efficacy profile of low-dose tocilizumab (TCZ) administered subcutaneously to patients with moderate COVID-19 pneumonia and hyperinflammation to prevent disease progression. METHODS: We retrospectively analyzed clinical characteristics and outcomes of patients with laboratory-confirmed bilateral COVID-19 pneumonia, hyperinflammation (C reactive protein ≥20 mg/dl), no hypoxemia (oxygen saturation >90%) and no contra-indications to TCZ, who were treated with subcutaneous TCZ (324 mg) administered within 48 hours from hospitalization on top of standard of care (SOC), and compared them with matched controls treated with SOC only before TCZ was available at our center. Clinical data were available for all patients until death or, for those discharged from hospital, until day 35. FINDINGS: Ten consecutive patients (6 males, median age 55 years) treated with TCZ on top of SOC, and ten patients (6 males, median age 56 years) treated with SOC only were included. TCZ was well-tolerated, with no clinically relevant adverse events. TCZ was associated with a reduction in CRP at day 1 (−50%, IQR −28 to −80) and day 3 (−89%, IQR −79 to −96; P = 0.005 for within-group), whereas there was no significant change in CRP values in the SOC group (P < 0.001 for between-groups comparisons at both time points). TCZ resulted in a parallel improvement of oxygenation, as assessed by the ratio of partial pressure of oxygen to fraction of inspired oxygen (P/F) ratio, which increased at day 1 (+11%, IQR + 6 to +16; P = 0.005 for within-group, and P = 0.006 for between-groups comparisons), and day 3 (+23%, IQR + 16 to +34; P = 0.005 for within-group, and P = 0.003 for between-groups comparisons). None of the TCZ-treated patients had disease progression defined as requirement of oxygen therapy or mechanical ventilation, whereas progression occurred in 5 (50%) patients among the SOC group. CONCLUSIONS: Low-dose subcutaneous TCZ may be a safe and promising therapeutic option administered on top of SOC to prevent disease progression in hospitalized patients with moderate COVID-19 and hyperinflammation.

hospitalization on top of standard of care (SOC), and compared them with matched controls treated with SOC only before TCZ was available at our center. Clinical data were available for all patients until death or, for those discharged from hospital, until day 35.

Findings: Ten consecutive patients (6 males, median age 55 years) treated with TCZ on top of SOC, and ten patients (6 males, median age 56 years) treated with SOC only were included.

TCZ was well-tolerated, with no clinically relevant adverse events. TCZ was associated with a reduction in CRP at day 1 (-50%, IQR -28 to -80) and day 3 (-89%, IQR -79 to -96; P=0.005 for within-group), whereas there was no significant change in CRP values in the SOC group (P<0.001 for between-groups comparisons at both time points). TCZ resulted in a parallel improvement of oxygenation, as assessed by the ratio of partial pressure of oxygen to fraction of inspired oxygen (P/F) ratio, which increased at day 1 (+11%, IQR +6 to +16; P=0.005 for within-group, and P=0.006 for between-groups comparisons), and day 3 (+23%, IQR +16 to +34; P=0.005 for within-group, and P=0.003 for between-groups comparisons). None of the TCZ-treated patients had disease progression defined as requirement of oxygen therapy or mechanical ventilation, whereas progression occurred in 5 (50%) patients among the SOC group.

Conclusions: Low-dose subcutaneous TCZ may be a safe and promising therapeutic option administered on top of SOC to prevent disease progression in hospitalized patients with moderate COVID-19 and hyperinflammation. infiltrates and rapidly progress to severe disease characterized by refractory hypoxemia requiring mechanical ventilation. [1] Elevated levels of C reactive protein (CRP) and

Interleukin-6 (IL-6), reflecting an hyperinflammatory response, identify patients with progression to refractory hypoxemia. [2] Subcutaneous tocilizumab (TCZ), a humanized anti-IL-6 receptor antibody, is approved for the treatment of rheumatoid arthritis, giant-cell arteritis and cytokine storm related to cancer therapeutics. Recent reports have suggested that high-dose intravenous TCZ (8 mg/kg) may be an effective treatment for severe-to-critical COVID-19 patients, for its ability to rapidly reduce fever and pro-inflammatory markers, and improve oxygenation. [3] [4] [5] [6] Whether TCZ can be administered subcutaneously in patients with moderate COVID-19 pneumonia and hyperinflammation to prevent progression to severe disease remains unknown.

We herein present a retrospective analysis of clinical characteristics and outcomes of ten consecutive patients (6 males, median age 55 years) with laboratory-confirmed COVID-19 bilateral pneumonia, hyperinflammation (CRP ≥ 20 mg/dl), no hypoxemia (oxygen saturation information was obtained by phone contact at 35 days. Data are presented as median and interquartile range (IQR). Within-group changes were compared using the Wilcoxon test for paired analysis, and between-groups differences were analyzed using the Mann-Whitney test for unpaired test.

Treatment with TCZ was well-tolerated with no clinically relevant adverse events. In particular, none of the patients experienced neutropenia (absolute neutrophil count <1000/mm3), bacterial infections, or liver injury (elevation in alanine aminotransferase 5 times above normal value) (Supplementary Table 1 ).

Treatment with TCZ was associated with a reduction in CRP at day 1 (-50%, IQR -28 to -80) and day 3 (-89%, IQR -79 to -96; P=0.005 for within-group), whereas there was no significant change in CRP values in the SOC group (P<0.001 for between-groups comparisons at both time points, Figure 1A ).

In parallel, treatment with TCZ resulted in an improvement of oxygenation, as assessed by the ratio of partial pressure of oxygen to fraction of inspired oxygen (P/F) ratio, which significantly increased at day 1 (+11%, IQR +6 to +16; P=0.005 for within-group, and P=0.006 for betweengroups comparisons), and day 3 (+23%, IQR +16 to +34; P=0.005 for within-group, and P=0.003 for between-groups comparisons, Figure 1A) . Table 2 ).

Our findings suggest that early IL-6 receptor blockade with TCZ may reduce the risk of progression to severe disease in hospitalized patients with moderate COVID-19 pneumonia and hyperinflammation. SARS-CoV viruses trigger an inflammasome-mediated response characterized by high levels of Interleukin-1 (IL-1), [7] and IL-1 blockade with anakinra or canakinumab has been shown to be associated with more favorable outcomes. [8, 9] Moreover, the IL-1 derived from the inflammasome, as well as the IL-1 isoform, released from dying alveolar epithelial cells, induce the expression of IL-6, which plays a key role in lung injury and refractory hypoxemia. Intravenous IL-6 blockers are often provided on a compassionateuse basis to severe-to-critical COVID-19 with reported beneficial effects, [3] [4] [5] [6] and are currently under investigation in randomized controlled trials. Recent studies reported on favorable outcomes with subcutaneous TCZ (324 mg) in patients with severe COVID-19. [10, 11] However, many patients with COVID-19 have moderate disease not requiring supplemental oxygen. Hyperinflammation may promote disease progression as indicated by higher levels of inflammatory biomarkers being associated with dire outcomes. [2] Notably, dexamethasone was recently reported to reduce mortality in COVID-19 patients with respiratory failure, but not in those not requiring supplemental oxygen. [12] The study has several limitations primarily being the small number of patients included, the non-random nature of the comparisons, and the possible immortal time bias.

We herein report on the innovative use of early subcutaneous TCZ in hospitalized patients with moderate COVID-19 who are at risk for progressive disease. Despite preliminary, our data 

The corresponding author had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: 

There was no funding source for this study. J o u r n a l P r e -p r o o f 

Acute complications and mortality in hospitalized patients with Coronavirus Disease 2019: a systematic review and metaanalysis

Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease

Effective treatment of severe COVID-19 patients with tocilizumab

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia

Pilot prospective open, single-arm multicenter study on off-label use of tocilizumab in patients with severe COVID-19

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-center retrospective cohort study

Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Canakinumab in a subgroup of patients with COVID-19

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyper-inflammation: a case-control study

World Health Organization, WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients